Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis<sup>*</sup>

LI Xing-xing; LI Dong; CUI Xiao-yun; ZHOU Kun; LIU Jing; LU Jin-jin; WU Yang; LIN Qian; LI Yan

doi:10.1007/s11655-023-3636-x

Your Location：

Home >

Browse articles >

Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*

Evidence-Based Integrative Medicine | Updated：2023-06-27

- Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*
- Chinese Journal of Integrative Medicine Vol. 29, Issue 7, Pages: 626-633(2023)
- Affiliations：
  
  1.Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing (100078), China
  2.Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing (100700), China
- Author bio：
  
  Dr. LI Yan, E-mail: erzitaba@163.com
- Funds：
- DOI：10.1007/s11655-023-3636-x
  CLC：
- Published：2023-07，
  
  Published Online：18 May 2023，
  
  Accepted：01 March 2023
Scan for full text
LI Xing-xing, LI Dong, CUI Xiao-yun, et al. Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*. [J]. Chinese Journal of Integrative Medicine 29(7):626-633(2023)
DOI：

LI Xing-xing, LI Dong, CUI Xiao-yun, et al. Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*. [J]. Chinese Journal of Integrative Medicine 29(7):626-633(2023) DOI： 10.1007/s11655-023-3636-x.

摘要

目的:

探讨黄芪甲苷Ⅳ (Astragaloside astragaloside Ⅳ

AS-Ⅳ) 对心力衰竭 (Heart failure

HF) 的心脏保护作用.

方法:

通过检索PubMed、EMBASE、Cochrane、Web of Science、SinoMed、万方数据库、维普数据库、中国知网

得到从建库至2021年11月1日发表的探究AS-Ⅳ对HF治疗作用的动物实验. 检测指标包括左室射血分数 (left ventricular ejection fraction

LVEF) 、左室缩短分数 (left ventricular fractional shortening

LVFS) 、左室舒张末期内径 (left ventricular end-diastolic dimension

LVEDD) 、左室收缩末期内径 (left ventricular end-systolic dimension

LVESD) 、左心室重量与体重之比 (left ventricular weight-to-body weight

LVW/BW) 和B型脑钠肽 (B-type brain natriuretic peptide

BNP) . 根据Cochrane手册进行过偏倚风险分析从而评估纳入研究的质量. 使用Stata 13.0进行Meta分析.

结果:

21篇文章涉及558只动物被纳入. 与对照组相比

AS-Ⅳ增加了LVEF (MD=6.97

95% CI=5.92至8.03

0.05

固定效应模型) 和LVFS (MD=7.01

95%CI=5.84至8.81

0.05

固定效应模型)

降低了LVEDD (MD=–4.24

95%CI=-4.74至-3.76

0.05

随机效应模型) 和LVESD (MD=–4.18

95%CI=-5.26至-3.10

0.05

随机效应模型) . 此外

AS-Ⅳ还降低了BNP和LVW/BW水平 (MD=-9.18

95%CI=–14.13至–4.22

0.05

随机效应模型; MD=–1.91

95%CI=–2.42至–1.39

0.05

随机效应模型) .

结论:

AS-Ⅳ是一种很有前途的HF治疗药物. 然而

这一结论需要未来在临床中得到证实.

Abstract

Objective:

To explore the cardioprotective effects of astragaloside Ⅳ (AS-Ⅳ) in heart failure (HF).

Methods:

PubMed

Excerpta Medica Database (EMBASE)

Cochrane Library

Web of Science

Wanfang Database

Chinese Bio-medical Literature and Retrieval System (SinoMed)

China Science and Technology Journal Database (VIP)

and China National Knowledge Infrastructure (CNKI) were searched from inception to November 1

2021 for animal experiments to explore AS-Ⅳ in treating HF in rats or mice. The left ventricular ejection fraction (LVEF)

left ventricular fractional shortening (LVFS)

left ventricular end-diastolic dimension (LVEDD)

left ventricular end-systolic dimension (LVESD)

left ventricular weight-to-body weight (LVW/BW) and B-type brain natriuretic peptide (BNP) were recorded. The qualities of included studies were assessed by the risk of bias according to the Cochrane handbook. Meta-analysis was performed using Stata 13.0.

Results:

Twenty-one articles involving 558 animals were considered. Compared with the control group

AS-Ⅳ improved cardiac function

specifically by increasing LVEF (mean difference (MD)=6.97

95% confidence interval (CI)=5.92 to 8.03

0.05; fixed effects model) and LVFS (MD=7.01

95% CI=5.84 to 8.81

0.05; fixed effects model)

and decreasing LVEDD (MD=–4.24

95% CI=–4.74 to –3.76

0.05; random effects model) and LVESD (MD=–4.18

95% CI=–5.26 to –3.10

0.05; fixed effects model). In addition

the BNP and LVW/BW levels were decreased in the AS-Ⅳ treatment group (MD=–9.18

95% CI=–14.13 to –4.22

0.05; random effects model; MD=–1.91

95% CI=–2.42 to –1.39

0.05; random effects model).

Conclusions:

AS-Ⅳ is a promising therapeutic agent for HF. However

this conclusion needs to be clinically validated in the future.

关键词

黄芪甲苷Ⅳ心力衰竭临床前证据系统综述

Keywords

astragalosideⅣheart failurepre-clinical evidencesystematic review

references

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Approach to Assess Adequacy of Acupuncture in Randomized Controlled Trials: A Systematic Review

Intelligent Chinese Medicine: A New Direction Approach for Integrative Medicine in Diagnosis and Treatment of Cardiovascular Diseases^*

Shexiang Tongxin Dropping Pill Allieviates Heart Failure via Extracellula Matrix-Receptor Interaction Pathways Based on RNA-Seq Transcriptomics and Experimental Studies^*

Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial

Related Author

No data

Related Institution

Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences

Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine

School of Health and Social Care, London South Bank University

The First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine

School of Traditional Chinese Medicine, Hunan University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰